Prostate Cancer

Active surveillance for men with favorable-risk prostate cancer is an effective management strategy, according to data from a prospective cohort study published in JAMA.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of transcriptomic signatures to aid in selection of patients with prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of new precision medicine therapies in prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of JNJ-6520 in prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of three studies into quality-of-life outcomes in metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CYCLONE 2 study into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a phase 1/phase 2 study into proteolysis-targeting chimeras in prostate cancer treatment, presented at ASCO Annual Meeting.

Robert A. Winn, MD, FAACR, first called for celebration.

Only a small percentage of men recommended to undergo genetic testing due to personal or family history of cancer actually received it, according to findings published in Journal of the National Comprehensive Cancer Network.

First-line prostate-specific antigen testing with second-line multiparametric MRI was a more cost effective screening strategy for prostate cancer than biparametric MRI as a first-line approach, a study showed.